Osteoporosis competitive landscape

While at Quintiles, Pieter Droppert was a lead CRA and European project manager for risedronate clinical trials, and he has since maintained an interest in osteoporosis new product development.

On the Biotech Strategy Blog, he discusses a recent review published in Nature Reviews Drug Discovery on the emerging treatments in development for osteoporosis.  He comments on some of the barriers to market entry that companies will increasingly face such as pressure not to do placebo-controlled trials with high fracture-risk subjects.

For further commentary and insight on the osteoporosis market, read the full post on Biotech Strategy Blog.

, , , , , , , ,

error: Content is protected !!